November 18, 2020 -- Memorial Sloan Kettering Cancer Center (MSK) has agreed to exclusively license its antibody fragments to CRISPR genome editing firm Caribou Biosciences to develop allogeneic cell therapies for cancer.
The agreement grants Caribou the right to its fully human anti-CD371 single-chain variable fragment (scFv) product. It also grants the company the right to intellectual property related to the field of allogeneic CD371-targeted cell therapies including chimeric antigen receptor (CAR)-T, CAR-natural killer (NK), or induced pluripotent stem cell (iPSC)-derived cell products. The antibody fragments will be used to create therapies for acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS).
The anti-CD371 scFvs were developed in a lab at MSK in collaboration with the Tri-Institutional Therapeutic Discovery Institute, a nonprofit drug discovery company wholly owned by MSK, Weill Cornell Medicine, and the Rockefeller University.
The financial terms of the agreement were not disclosed.